



## Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting

October 23, 2025

ZUG, Switzerland, Oct. 23, 2025 (GLOBE NEWSWIRE) -- [Pharvaris](#) (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of two abstracts for oral presentation and six for poster presentation at the American College of Allergy, Asthma, and Immunology (ACAAI) 2025 Annual Scientific Meeting to be held from November 6-10, in Orlando, Florida.

Details of the presentations are as follows:

**ACAAI 2025**, Orlando, Florida, November 6-10, 2025.

### *Oral Presentations*

- **Title:** Clinical Validation of a Kinin Biomarker Assay to Characterize Bradykinin-Mediated Angioedema  
**Presenter:** Evangelia Pardali, Ph.D.  
**Format:** Oral Presentation  
**Date, time:** Saturday, November 8, 4:43 p.m. ET
- **Title:** Long-Term Safety and Efficacy of Oral Deucricitbant for Prophylaxis in Hereditary Angioedema: CHAPTER-1 Open-Label Extension  
**Presenter:** Marc A. Riedl, M.D., M.S.  
**Format:** Oral Presentation  
**Date, time:** Saturday, November 8, 4:53 p.m. ET

### *Poster Presentations*

- **Title:** Long-Term Prophylactic Treatment with Oral Deucricitbant Improved Disease Control and Health-Related Quality of Life in Hereditary Angioedema: CHAPTER-1  
**Presenter:** Michael E. Manning, M.D.  
**Format:** Poster Presentation  
**Date, time:** Friday, November 7, 2:35 p.m. ET
- **Title:** Long-Term Safety and Efficacy of Oral Deucricitbant for Treatment of Hereditary Angioedema Attacks: RAPIDe-2 Results  
**Presenter:** John Anderson, M.D.  
**Format:** Poster Presentation  
**Date, time:** Friday, November 7, 2:35 p.m. ET
- **Title:** Deucricitbant vs. Standard of Care in Hereditary Angioedema: A Propensity Score-Matched Analysis  
**Presenter:** Mark D. Scarupa, M.D.  
**Format:** Poster Presentation  
**Date, time:** Friday, November 7, 4:35 p.m. ET
- **Title:** Durability of Response to Single Dose Oral Deucricitbant for On-Demand Treatment of Hereditary Angioedema Attacks  
**Presenter:** Joshua S. Jacobs, M.D.  
**Format:** Poster Presentation  
**Date, time:** Friday, November 7, 5:05 p.m. ET
- **Title:** Outcomes of Deucricitbant-Treated Upper Airway and Laryngeal Hereditary Angioedema Attacks: RAPIDe-2 Part A Results  
**Presenter:** John Anderson, M.D.  
**Format:** Poster Presentation  
**Date, time:** Friday, November 7, 5:20 p.m. ET
- **Title:** Sustained Therapeutic Exposure with Once-Daily Oral Deucricitbant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks  
**Presenter:** Zhi-Yi Zhang, Ph.D.  
**Format:** Poster Presentation  
**Date, time:** Friday, November 7, 5:35 p.m. ET

The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: <https://ir.pharvaris.com/news-events/events-presentations>.

**About Pharvaris**

Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of oral therapies to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucricitibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit <https://pharvaris.com/>.

Contact Maggie Beller Executive Director, Head of Corporate and Investor Communications [maggie.beller@pharvaris.com](mailto:maggie.beller@pharvaris.com)